Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 317 participants.
Also called NCT01233622
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 317 participants
- Sponsor
- Registry
-
NCT01233622
-
- Other papers using this trial's data
- Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Australia, Germany, Hungary, Italy, Mexico, Philippines, Romania, South Korea, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT01233622. Randomized; double masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2011-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride
- Acronym
- Vildagliptin
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Vildagliptin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novartis
Record details
- Record id
cardio:ct-nct01233622- Content hash
1ea2830cb3df1fcdb8e4cc5c5a47659392f66ba3208b909797e9b7e707c6f4d0